A new study suggests that Amgen’s new cholesterol drug Repatha can be very effective in helping patients avoid heart disease. It’s also been found that the drug works very well in lowering LDL cholesterol levels, while reducing the odds of patients dying or getting hospitalized following cardiac events. However, it would also appear that the new medication is extremely expensive for the average consumer, which is priced at $ 14,000 a year.
According to a report from Kaiser Health News, Repatha is a man-made antibody with the generic name evolocumab. As a form of medication for heart disease, the drug has proven to be effective in reducing the combined risk of heart attack, stroke, and cardiovascular-related death by about 20 percent. The drug was first approved in 2015, at a point where it was known that it could reduce levels of bad cholesterol, but not sure whether it could prevent heart attacks.